AI Article Synopsis

  • Acoustic radiation force impulse point shear wave elastography (ARFI-pSWE) is a technique used to measure liver stiffness by analyzing shear-wave velocity (SWV), but its effectiveness in assessing liver fibrosis in chronic hepatitis B (CHB) patients was previously unclear.
  • A study involving 114 adult CHB patients determined that ARFI-pSWE has a strong correlation with FibroScan, suggesting it is a reliable method for staging liver fibrosis.
  • The optimal SWV cut-off values found were 1.37 m/s for significant fibrosis and 1.70 m/s for cirrhosis, with high sensitivity and specificity for both conditions, indicating ARFI-pSWE's potential as a diagnostic tool in clinical settings

Article Abstract

 Acoustic radiation force impulse point shear wave elastography (ARFI-pSWE), measuring shear-wave velocity (SWV), has been utilized to examine the liver stiffness caused by different etiologies. However, information on its reliability in staging liver fibrosis in chronic hepatitis B (CHB) patients is scarce.  The aim of the study is to examine the diagnostic performance of ARFI-pSWE and determine the optimal SWV cut-off values to predict significant fibrosis ( ≥2) and cirrhosis (F4) in CHB patients.  All 114 adult CHB patients visiting the University Medical Center, Ho Chi Minh City, Vietnam between February 2019 and March 2021 underwent liver stiffness measurement using ARFI-pSWE and FibroScan. SWV results were tested against FibroScan for sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). The area under the receiver operating characteristic (AUROC) curve was used to identify the optimal SWV cut-off values.  There was a strong agreement between ARFI-pSWE and FibroScan (  = 0.92, <0.001). The optimal SWV cut-off value for detecting significant fibrosis was 1.37 m/s with an AUROC of 0.975, sensitivity of 83.3%, specificity of 100%, PPV of 100%, and NPV of 81%. The optimal cut-off value for predicting cirrhosis was 1.70 m/s with an AUROC of 0.986, sensitivity of 97%, specificity of 93%, PPV of 95%, and NPV of 96%.  ARFI-pSWE could be an effective technique for evaluating liver fibrosis in CHB patients. SWV cut-off values of 1.37 and 1.70 m/s could be used to diagnose significant fibrosis and cirrhosis, respectively.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514909PMC
http://dx.doi.org/10.1055/s-0042-1755251DOI Listing

Publication Analysis

Top Keywords

chb patients
12
diagnostic performance
8
radiation force
8
force impulse
8
liver fibrosis
8
chronic hepatitis
8
liver stiffness
8
optimal swv
8
swv cut-off
8
cut-off values
8

Similar Publications

The natural stages of chronic hepatitis B can be divided into four stages according to changes in virology, biochemistry, and pathology. However, there have been significant differences in the recommended stage criteria in the several major guidelines for chronic hepatitis B, especially regarding the immune tolerance phase. Inconsistent standards of indicators for different stages resulted in some problems, such as incorrect stage, uncertain stages and poor comparation of related studies.

View Article and Find Full Text PDF

This study aims to construct and validate noninvasive diagnosis models for evaluating significant liver fibrosis in patients with chronic hepatitis B (CHB). A cohort of 259 CHB patients were selected as research subjects. Through random grouping, 182 cases were included in the training set and 77 cases in the validation set.

View Article and Find Full Text PDF

The exclusion of cirrhosis is important in chronic hepatitis B (CHB) patients with normal alanine aminotransferase (ALT). We aimed to optimise the performance of the aspartate aminotransferase to platelet ratio index (APRI) and fibrosis score based on four factors (FIB-4) to exclude cirrhosis in these patients. Five hundred and eighty four patients with normal ALT who underwent liver biopsy were included in the study.

View Article and Find Full Text PDF

Determinants of outcomes in patients with hepatitis B virus-decompensated cirrhosis.

Sci Rep

January 2025

Department of Public Health, College of Public Health, China Medical University, No. 100, Sec. 1, Jingmao Rd., Beitun Dist., Taichung, 406040, Taiwan.

The role of pre-treatment HBV DNA levels on the prognosis of hepatitis B virus-related decompensated cirrhosis is unclear. This study investigated the effects of pre-treatment HBV DNA and other determinants on short-term and long-term survival of chronic hepatitis B (CHB) patients with decompensated cirrhosis. A total of 278 cirrhotic decompensated CHB patients treated with entecavir or tenofovir disoproxil fumarate were retrospectively enrolled.

View Article and Find Full Text PDF

Hepatitis B virus-induced cirrhosis: Mechanisms, global variations, and treatment advances.

World J Hepatol

December 2024

Institute of Liver Diseases, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun 130061, Jilin Province, China.

We focus on hepatitis B virus (HBV)-induced cirrhosis, global differences, and the evolution of antiviral treatment strategies. Chronic HBV (CHB) infection affects more than 250 million people globally, leading to cirrhosis and hepatocellular carcinoma. The aim of this article was to synthesize the current understanding of the pathophysiological mechanisms and clinical consequences of HBV-induced cirrhosis, and explore differences in disease progression between geographic regions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!